Background: Arteriovenous (AV) access graft complications represent a serious complication in patients undergoing hemodialysis. Angiography is one method of visualizing them. However, angiography is not always an effective means of detecting lesions that occur in this context. Intravascular ultrasound (IVUS) is an adjunct modality used to identify stenoses responsible for failing access by identifying multiple stenoses, including those that are most severe. The purpose of this study was to define the value of IVUS in patients with failing AV access grafts by comparing digital subtraction angiography (DSA) alone with DSA followed by IVUS.
Arteriovenous (AV) access graft complications are responsible for a large proportion of morbid events in the hemodialysis population. The rate of complications rises considerably once AV access fails, justifying surveillance for failing accesses and correction of stenotic lesions before thrombosis occurs. In this regard, the Kidney Disease Outcomes Quality Initiative Work Group recommended serial access flow, venous dialysis pressure measurements, or duplex ultrasound imaging as the preferred monitoring techniques for monitoring of AV access. Unmasked abnormalities should trigger the performance of angiography to identify and to correct culprit lesions.
Angiography, however, is neither sensitive nor specific for the detection of coronary lesions. In this regard, intravascular ultrasound (IVUS) has been studied as an adjunctive modality that can be used in addition to angiography. [1] [2] [3] [4] Despite the potential of IVUS to improve diagnostic accuracy, comparative data regarding its use remain limited. The current study was a prospective, randomized trial to define the value of IVUS in patients with failing AV access grafts, comparing digital subtraction angiography (DSA) alone with DSA followed by IVUS in this setting.
METHODS
This pilot study of IVUS imaging during endovascular interventions of failing hemodialysis access grafts was a prospective, randomized, nonblinded, single-center study comparing IVUS with traditional DSA in patients with failing hemodialysis access grafts. It was conducted at the Dialysis Access Institute at the Regional Medical Center (Orangeburg, SC). The study randomized 100 hemodialysis patients presenting with failing AV access and considered for endovascular intervention (Fig 1) . Patients were randomized on the day of intervention, also referred to as day zero. Randomization was conducted through use of numbered envelopes opened by the site on enrollment. The numbered envelope informed the site as to whether a given patient would receive IVUS. Patients who received IVUS were enrolled in the test group, and those who did not enrolled in the control group. This pilot study did not involve formal hypothesis testing; as such, the sample size was not calculated in a statistically driven manner. This pilot study was descriptive in nature, and no formal hypothesis testing or powered sample size calculations were performed. [5] [6] [7] Eligibility criteria included patients with slow flow for a failing AV access graft that previously provided access for at least one successful hemodialysis session, aged 18 to 85 years, with eligibility for endovascular intervention. Patients scheduled for kidney transplantation or planned switch to peritoneal dialysis within the next 6 months were ineligible for inclusion, as were pregnant or lactating patients and those with a life expectancy of <6 months. The determination of slow flow through the access was site reported and represented a situation in which flow was insufficient to support hemodialysis.
The primary study end point was the time to AV access graft failure after the index intervention, assessed through 6 months after the index procedure. All patients had AV grafts, with none of the patients having AV fistulas. This allowed investigators to focus on the ability of IVUS to detect failing AV access grafts. Interventions in the control group were guided by DSA alone, whereas interventions in the test group were guided by DSA followed by IVUS. IVUS was performed using the Eagle Eye Platinum Catheter (Volcano Corporation, San Diego, Calif). ChromaFlo (Volcano Corporation) was also part of the workflow for all index procedure interrogations using IVUS. Secondary analyses included the influence of DSA or DSA and IVUS on index procedure decision-making, percentage of patients with AV access graft reinterventions or discontinuation at 3 months, and percentage of patients with AV access graft reinterventions or discontinuation at 6 months. It was possible for more than one adjustment to patient management to be selected per lesion. The operator's discretion was used to determine the timing and nature of potential reintervention. Operators decided whether to reintervene on the basis of a number of factors, including degree of stenosis and the patient's clinical profile, among others.
Data analysis was conducted using descriptive statistics. In light of the non-normal distribution of outcome data, standard and nonparametric metrics were measured, including mean, median, minimum, maximum, standard deviation, and interquartile range (IQR). Stratification of results across subgroups was considered as part of the analysis and as a basis for informing inclusion and exclusion criteria for future studies. Normality was assessed with the ShapiroWilks test. Data from the groups were compared with the Student t-test when the data were normally distributed and with the Mann-Whitney test when not. The probability of graft failure as a function of time was analyzed using Kaplan-Meier curves. Groups were compared with the Student t-test. Differences were considered statistically significant when the twotailed P value was < .05.
This study was conducted in a manner that was compliant with the principles outlined in the Declaration of Helsinki. The protocol and informed consent were approved by an Institutional Review Board, and all subjects provided informed consent to participate in the study before the index procedure.
RESULTS
Baseline demographic data of the patients can be found in Table I . The differences between groups were not significant with respect to baseline demographic and comorbidity data. To further ensure that the groups were matched, they were also compared in terms of baseline AV graft characteristics and characteristics of index procedure performed. Differences between groups were not significant with respect to any of the metrics related to baseline AV graft characteristics or the nature of the index procedure performed. Baseline AV graft characteristics can be found in Table II . Of the 100 patients, 93 patients were studied, as 7 (3 from the control group and 4 from the test group) were considered unevaluable. There were two operators; one operator performed approximately 90% of the procedures, and the other operator performed approximately 10% of the 
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Recommendation:
The authors suggest that a trial adequately powered and with longer follow-up be conducted to discern if intravascular ultrasound in addition to angiography has clinical benefit in evaluating failing arteriovenous grafts. Patients in the test group experienced a procedure time that on average was 5.7 minutes less than the procedure time experienced by patients in the control group. Patients in the test group were exposed to less fluoroscopy time (6.6 minutes vs 7.8 minutes) and contrast material volume (105 mL vs 127 mL) than patients in the control group. The average number of lesions treated per patient was greater in the control group (1.5) than in the test group (1.2). The index procedure summary can be found in Table III . Although the greater number of lesions per patient in the control group was surprising, the difference was not statistically significant (P ¼ .11). None of the lesions were classified as calcific in nature. Stent types included Gore Viabahn (W. L. Gore & Associates, Flagstaff, Ariz) and Bard E$Luminexx (Bard, Murray Hill, NJ). Balloon sizes included 7 Â 8 mm, 9 Â 5 mm, 8 Â 8 mm, 8 Â 4 mm, 9 Â 4 mm, and 9 Â 2 mm.
The number of days to AV graft reintervention or AV graft discontinuation was numerically higher in the test group than in the control group (Fig 2) , with a median of 61 days (IQR, 27-103 days) vs 30 days (IQR, 9-83 days), respectively. The difference did not attain statistical significance (P ¼ .16), but a post hoc power calculation suggested that approximately 150 subjects would have been required to achieve 80% power at a two-tailed a level of .05. Detailed results limited to patients who experienced reintervention or AV access graft discontinuation within 6 months can be seen in Table IV . Results presented in Table IV were limited to patients who experienced an AV graft failure within 6 months of the index procedure. As such, the total number of patients in Table IV (59) is much smaller than the total number of patients in Table I (100), as patients who did not experience an AV graft failure were excluded from the results presented in Table IV . Of the 59 patients included in this analysis, 30 belonged to the test group and 29 belonged to the control group.
Separate Kaplan-Meier curves were created for reintervention and AV graft discontinuation. At 6 months, approximately 35% of patients in both the control and test groups remained free from reinterventions (P ¼ .88; Fig 3) . At 6 months, approximately 75% of patients in the control group and 80% of patients in the test group remained free from AV graft discontinuation or abandonment (P ¼ .45; Fig 4) . Of the 58 lesions that were treated at time of index procedure in the test arm, IVUS altered treatment plans in 44 (76%) of those lesions. The most frequent changes to the treatment plans were additional balloon angioplasty (86%), stent implantation (9.1%), and additional thrombectomy (4.5%). When an intervention was performed in the 
DISCUSSION
The primary objective of this pilot study was to provide initial data on the value of adding IVUS to DSA in patients with failing or failed AV access grafts. The study contained a number of secondary objectives, one of which was to determine how often addition of IVUS to DSA at time of index procedure resulted in revised management plans in the treatment group.
It was hypothesized that patients in the treatment group would experience greater average times to AV graft failure than patients in the control group as a result of the increased sensitivity of IVUS compared with DSA. Whereas the difference between groups with respect to the primary end point was not significant, the differences were fairly large on both an absolute and relative basis. The median time to AV graft discontinuation in the treatment group (61.0 days) was more than twice as large as in the control group (30.0 days). The median time to reintervention in the control group was rapid at 30.0 days. This showed that failures occurred early. The timing and nature of the reintervention were left to the operator's discretion. The fact that patients in the treatment group returned more frequently (33%) than patients in the control group (24%) after 90 days following the index procedure was somewhat difficult to explain. One possible explanation for this is the fact that a higher percentage of patients in the control group (34%) than in the treatment group (17%) returned in the first 15 days after the index procedure.
Secondary results indicated that IVUS altered management plans in 44 of 58 (76%) patients, whereas both groups demonstrated similar rates of one or more AV graft reinterventions or discontinuation at 3 months and 6 months. The frequency with which IVUS led to revised treatment plans did not come as a surprise when considering the ability of IVUS to detect lesions that DSA may have missed. The similar rate of one or more AV graft reinterventions or discontinuation between groups was surprising on the surface but less surprising in the context of how the end point was constructed and measured. Because IVUS was thought to detect lesions that DSA would miss, one might have expected the rate to be higher in the control group than in the treatment group. One counterintuitive finding was that patients in the test group experienced mean fluoroscopy times and contrast material volumes less than patients in the control group did. A possible explanation for this observation is the fact that patients in the test group needed fewer obliquities when imaged using IVUS and DSA than patients in the control group, who underwent longer and more time-consuming angiography without the benefit of IVUS interrogation. It is also possible that patients in the control group demonstrated concerns requiring AV graft reintervention or discontinuation that on average were more severe than in patients in the treatment group. Previous work going back as far as 1991 has shown that IVUS has potential to identify disease that may not be detected by angiography and that use of IVUS in conjunction with angiography could be more sensitive in the detection of intraluminal thrombus and dissection than angiography alone. [8] [9] [10] A paper from 1991 found that IVUS was far more successful than angiography in detecting intraluminal thrombus and dissections. The rates of detection of intraluminal thrombus and dissections using IVUS were 16% and 42%, respectively. The rates of detection of intraluminal thrombus and dissections using angiography were 3% and 3%, respectively. 8 Authors of one of the studies, which evaluated IVUS as a tool for AV graft assessment, concluded that IVUS yielded additional information that could help understand, reduce, and prevent common problems associated with vascular access. This extra information was in addition to the ability of IVUS to detect findings obtained using angiography. 9 One of the more recently published studies (2014) concluded that IVUS may play an important role in salvaging hemodialysis fistulas. To the best of the investigators' knowledge, this study represented the first reported use of IVUS to salvage a hemodialysis graft using a contrastfree technique. 11 No attempt was made to determine whether IVUS could be performed by itself in the absence of DSA. A number of conclusions can be drawn from the data and results of this study. One conclusion was that IVUSbased imaging of failing hemodialysis AV access using the Eagle Eye Platinum Catheter is safe. The authors concluded that IVUS imaging of the arterial inflow vessel, AV graft conduit, and venous outflow vessel is feasible. Study investigators considered ChromaFlo IVUS imaging beneficial for the purpose of lumen delineation. One limitation of the study is that it was unblinded. Investigators knew whether they were operating on a patient in the control arm or in the treatment arm. It is possible that operators had a preference for or against use of IVUS in addition to DSA. Overcoming this limitation could be a challenge moving forward as it is difficult to blind patients and investigators in light of the design used in this study. Another limitation is small sample size, which leads to a larger standard error and less precise estimates of effect than in the case of a larger study. An additional limitation of the study design is that it allowed subjects with HeRO grafts to be enrolled. The small number of subjects with HeRO devices as well as the relatively equal percentage of subjects in the two groups in part protected against confounding of the results. One aspect of study design that may not be a limitation but may perhaps be a bias is the fact that patients in the test group received imaging using IVUS in addition to angiography. As such, patients in the test group were imaged by two modalities, whereas those in the control group were imaged with just one modality. With respect to this study, some of the limitations could be used as a basis for areas of future investigation. One such area would be an attempt to design a study that uses an imaging core laboratory and blinded adjudication of end points. This could help reduce some of the operators' biases with respect to imaging modalities. Another area of future study could involve an expansion of the size and scope of this study. Suggestions for a more thorough study involve an increased sample size, the use of a multicenter study, and an international pool of patients, among others. Another change that can be made to a future study would be limiting enrollment to patients who enter the study for their first intervention or, if that is not feasible, prohibiting patients with more than two or three prior interventions from inclusion.
CONCLUSIONS
This study provides further evidence that supports addition of IVUS to standard angiography during endovascular interventions of failing hemodialysis access grafts. As previously published work has noted, IVUS can also play an important role in identifying central venous outflow obstruction and devising treatment plans for patients who suffer from this condition. 12 Results of this study suggest that addition of IVUS to standard angiography during endovascular interventions of failing hemodialysis access grafts may extend time to first reintervention. Longer term follow-up and a more comprehensive study design would be recommended to further investigate the use of IVUS in this context. 
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